Analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
A number of other brokerages have also commented on CYCC. Roth Mkm raised their price objective on shares of Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, December 19th. Brookline Capital Management downgraded Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th.
View Our Latest Stock Report on CYCC
Cyclacel Pharmaceuticals Stock Up 16.8 %
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last announced its quarterly earnings data on Tuesday, March 19th. The biotechnology company reported ($6.23) EPS for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million for the quarter. As a group, equities research analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in CYCC. Schonfeld Strategic Advisors LLC increased its holdings in Cyclacel Pharmaceuticals by 25.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 770,400 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 155,200 shares during the period. Renaissance Technologies LLC increased its stake in Cyclacel Pharmaceuticals by 166.0% in the third quarter. Renaissance Technologies LLC now owns 167,600 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 104,600 shares during the last quarter. Millennium Management LLC acquired a new position in Cyclacel Pharmaceuticals during the second quarter valued at approximately $113,000. Two Sigma Investments LP bought a new stake in Cyclacel Pharmaceuticals during the third quarter worth $98,000. Finally, HRT Financial LP acquired a new stake in shares of Cyclacel Pharmaceuticals in the 4th quarter valued at $27,000. Institutional investors and hedge funds own 23.58% of the company’s stock.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
Featured Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- What is MarketRankā¢? How to Use it
- United Airlines Soars on Earnings Beat
- How to Invest in Small Cap StocksĀ
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What does consumer price index measure?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.